Update Mammakarzinom 2023 Teil 3 – Expertenmeinungen zu Brustkrebs in frühen Krankheitsstadien

Zusammenfassung

In einem 2-jährigen Rhythmus fand in St. Gallen in früheren Jahren und nun in Wien die „St. Gallen (SG) International Breast Cancer Conference“ statt. Dieses Jahr (2023) wurde diese Konferenz, die sich mit der Behandlung von Patientinnen in Frühstadien des Mammakarzinoms beschäftigt, zum 18. Mal durchgeführt. Am Ende dieser 4-tägigen Veranstaltung wird eine Panel-Abstimmung abgehalten, bei der ein Expertengremium über aktuelle kontroverse Themen bei der Behandlung von Brustkrebspatientinnen in Frühstadien abstimmt. Hierbei werden die Fragen meistens so formuliert, dass klinisch realistische Fälle – oft in verschiedenen Modifikationen – vorgestellt werden. Diese Übersichtsarbeit berichtet von den Abstimmungsergebnissen und fasst die mit den jeweiligen Fragen verbundene Datenlage zusammen.

Abstract

The St. Gallen (SG) International Breast Cancer Conference is held every two years, previously in St. Gallen and now in Vienna. This year (2023) marks the eighteenth edition of this conference, which focuses on the treatment of patients with early-stage breast carcinoma. A panel discussion will be held at the end of this four-day event, during which a panel of experts will give their opinions on current controversial issues relating to the treatment of early-stage breast cancer patients. To this end, questions are generally formulated in such a way that clinically realistic cases are presented – often including poignant hypothetical modifications. This review reports on the outcome of these discussions and summarises the data associated with individual questions raised.

Schlüsselwörter

Brustkrebs - Therapieempfehlung - Chemotherapie - Antihormontherapie

Key words

breast cancer - therapy recommendation - chemotherapy - endocrine therapy

Publication History

Received: 29 June 2023

Accepted: 27 July 2023

Article published online:
08 December 2023

• Literatur

• 1 Partridge AH, Niman SM, Ruggeri M. et al. Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer. San Antonio Breast Cancer Symposium 2022; 2022: GS4-09
• 2 Hu C, Hart SN, Gnanaolivu R. et al. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med 2021; 384: 440-451 DOI: 10.1056/NEJMoa2005936.
• 3 Dorling L, Carvalho S, Allen J. Breast Cancer Association Consortium. et al. Breast Cancer Risk Genes – Association Analysis in More than 113000 Women. N Engl J Med 2021; 384: 428-439 DOI: 10.1056/NEJMoa1913948.
• 4 Couch FJ, Hart SN, Sharma P. et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol 2015; 33: 304-311 DOI: 10.1200/JCO.2014.57.1414.
• 5 Fasching PA, Yadav S, Hu C. et al. Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer-Association With Patient and Disease Characteristics and Effect on Prognosis. J Clin Oncol 2021; 39: 1619-1630 DOI: 10.1200/JCO.20.01200.
• 6 Rhiem K, Auber B, Briest S. et al. Consensus Recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer. Breast Care (Basel) 2022; 17: 199-207 DOI: 10.1159/000516376.
• 7 Rhiem K, Bucker-Nott HJ, Hellmich M. et al. Benchmarking of a checklist for the identification of familial risk for breast and ovarian cancers in a prospective cohort. Breast J 2019; 25: 455-460 DOI: 10.1111/tbj.13257.
• 8 Hauke J, Horvath J, Gross E. et al. Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer. Cancer Med 2018; 7: 1349-1358 DOI: 10.1002/cam4.1376.
• 9 Wunderle M, Gass P, Haberle L. et al. BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients. Breast Cancer Res Treat 2018; 171: 85-94 DOI: 10.1007/s10549-018-4797-8.
• 10 Foulkes WD. The ten genes for breast (and ovarian) cancer susceptibility. Nat Rev Clin Oncol 2021; 18: 259-260 DOI: 10.1038/s41571-021-00491-3.
• 11 Cardoso F, vanʼt Veer LJ, Bogaerts J. et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med 2016; 375: 717-729 DOI: 10.1056/NEJMoa1602253.
• 12 Paik S, Shak S, Tang G. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826 DOI: 10.1056/NEJMoa041588.
• 13 Sparano JA, Gray RJ, Makower DF. et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 2018; 379: 111-121 DOI: 10.1056/NEJMoa1804710.
• 14 Sparano JA, Gray RJ, Makower DF. et al. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 2015; 373: 2005-2014 DOI: 10.1056/NEJMoa1510764.
• 15 Wang Y, Li Y, Liang J. et al. Chemotherapy-Induced Amenorrhea and Its Prognostic Significance in Premenopausal Women With Breast Cancer: An Updated Meta-Analysis. Front Oncol 2022; 12: 859974 DOI: 10.3389/fonc.2022.859974.
• 16 Guerrero A, Gavila J, Folkerd E. et al. Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane. Ann Oncol 2013; 24: 674-679 DOI: 10.1093/annonc/mds464.
• 17 Ruddy KJ, Schaid DJ, Partridge AH. et al. Genetic predictors of chemotherapy-related amenorrhea in women with breast cancer. Fertil Steril 2019; 112: 731-739.e1 DOI: 10.1016/j.fertnstert.2019.05.018.
• 18 Davies C, Pan H, Godwin J. et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013; 381: 805-816 DOI: 10.1016/S0140-6736(12)61963-1.
• 19 Gray RG, Rea D, Handley K. et al , and on behalf of the aTTom Collaborative Group. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 2013; 31 (Suppl. 18) 5-5
• 20 Petrelli F, Coinu A, Cabiddu M. et al. Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials. Breast Cancer Res Treat 2013; 140: 233-240 DOI: 10.1007/s10549-013-2629-4.
• 21 Goss PE, Ingle JN, Martino S. et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005; 97: 1262-1271 DOI: 10.1093/jnci/dji250.
• 22 Goss PE, Ingle JN, Pritchard KI. et al. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. N Engl J Med 2016; 375: 209-219 DOI: 10.1056/NEJMoa1604700.
• 23 Jakesz R, Greil R, Gnant M. et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst 2007; 99: 1845-1853 DOI: 10.1093/jnci/djm246.
• 24 Mamounas EP, Bandos H, Lembersky BC. et al. Ten-year results from NRG Oncology/NSABP B-42: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor+ breast cancer (BC) who have completed previous adjuvant therapy with an aromatase inhibitor (AI). San Antonio Breast Cancer Symposium 2019; 2019: GS4-01
• 25 Del MastroL, Mansutti M, Bisagni G. et al. Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2021; 22: 1458-1467 DOI: 10.1016/S1470-2045(21)00352-1.
• 26 Gnant M, Fitzal F, Rinnerthaler G. et al. Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer. N Engl J Med 2021; 385: 395-405 DOI: 10.1056/NEJMoa2104162.
• 27 Johnston SRD, Toi M, OʼShaughnessy J. et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol 2023; 24: 77-90 DOI: 10.1016/S1470-2045(22)00694-5.
• 28 Harbeck N, Rastogi P, Martin M. et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol 2021; 32: 1571-1581 DOI: 10.1016/j.annonc.2021.09.015.
• 29 Johnston SRD, Harbeck N, Hegg R. et al. ; monarchE Committee Members and Investigators. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol 2020; 38: 3987-3998 DOI: 10.1200/JCO.20.02514.
• 30 Slamon D, Stroyakovskiy D, Yardley D. et al. Phase III NATALEE trial of ribociclib + endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer. ASCO Annual Meeting 2023; 2023: LBA500
• 31 Tarantino P, Burstein HJ, Lin NU. et al. Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?. Ann Oncol 2022; 33: 234-238 DOI: 10.1016/j.annonc.2021.12.004.
• 32 Royce M, Mulkey F, Osgood C. et al. US Food and Drug Administration Expanded Adjuvant Indication of Abemaciclib in High-Risk Early Breast Cancer. J Clin Oncol 2023; 41: 3456-3457 DOI: 10.1200/JCO.23.00615.
• 33 United States Food and Drug Administration (FDA). FDA expands early breast cancer indication for abemaciclib with endocrine therapy. 2023 Online (Stand: 03.04.2023): https://www.fda.gov/drugs/resourcesinformation-approved-drugs/fda-expands-early-breast-cancerindication-abemaciclib-endocrine-therapy
• 34 Coutant C, Olivier C, Lambaudie E. et al. Comparison of Models to Predict Nonsentinel Lymph Node Status in Breast Cancer Patients With Metastatic Sentinel Lymph Nodes: A Prospective Multicenter Study. J Clin Oncol 2009; 27: 2800-2808 DOI: 10.1200/jco.2008.19.7418.
• 35 Memorial Sloan Kettering Cancer Center. Breast Cancer Nomogram: Breast Additional Non SLN Metastases. 2023 Online (Stand: 02.04.2023): https://nomograms.mskcc.org/Breast/BreastAdditionalNonSLNMetastasesPage.aspx
• 36 MD Anderson Cancer Center. Breast Cancer Nomogram to Predict Additional Positive Non-SLN, without Neoadjuvant Chemotherapy. 2023 Online (Stand: 03.04.2023): http://www3.mdanderson.org/app/medcalc/bc_nomogram2
• 37 Sparano J, Gray RJ, Makower D. et al. Trial Assigning Individualized Options for Treatment (TAILORx): An update including 12-year event rates. San Antonio Breast Cancer Symposium 2022; 2022: GS1-05
• 38 Geyer jr CE, Garber JE, Gelber RD. et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol 2022; 33: 1250-1268 DOI: 10.1016/j.annonc.2022.09.159.
• 39 Tutt ANJ, Garber JE, Kaufman B. et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med 2021; 384: 2394-2405 DOI: 10.1056/NEJMoa2105215.
• 40 Schmid P, Cortes J, Dent R. et al. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med 2022; 386: 556-567 DOI: 10.1056/NEJMoa2112651.
• 41 Schmid P, Cortes J, Pusztai L. et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med 2020; 382: 810-821 DOI: 10.1056/NEJMoa1910549.
• 42 Bonadio RC, Tarantino P, Testa L. et al. Management of patients with early-stage triple-negative breast cancer following pembrolizumabbased neoadjuvant therapy: What are the evidences?. Cancer Treat Rev 2022; 110: 102459 DOI: 10.1016/j.ctrv.2022.102459.
• 43 Ditsch N, Kolberg-Liedtke C, Friedrich M. et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021. Breast Care (Basel) 2021; 16: 214-227 DOI: 10.1159/000516419.
• 44 Fasching PA, Hein A, Kolberg HC. et al. Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer – A single-arm phase II trial (Neo-Immunoboost, AGO-B-041). Eur J Cancer 2023; 184: 1-9 DOI: 10.1016/j.ejca.2023.01.001.
• 45 Hahnen E, Lederer B, Hauke J. et al. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. JAMA Oncol 2017; 3: 1378-1385 DOI: 10.1001/jamaoncol.2017.1007.
• 46 von Minckwitz G, Procter M, de Azambuja E. et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med 2017; 377: 122-131 DOI: 10.1056/NEJMoa1703643.
• 47 Piccart M, Procter M, Fumagalli D. et al. APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Yearsʼ Follow-Up. J Clin Oncol 2021; 39: 1448-1457 DOI: 10.1200/JCO.20.01204.
• 48 Loibl S, Jassem J, Sonnenblick A. et al Updated Results of Aphinity at 8.4 years median follow up. ESMO Virtual Plenary 2022; July 14, 2022
• 49 von Minckwitz G, Huang CS, Mano MS. et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med 2019; 380: 617-628 DOI: 10.1056/NEJMoa1814017.
• 50 Martin M, Holmes FA, Ejlertsen B. et al. Neratinib after trastuzumabbased adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2017; 18: 1688-1700 DOI: 10.1016/S1470-2045(17)30717-9.
• 51 Chan A, Moy B, Mansi J. et al. Final Efficacy Results of Neratinib in HER2- positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. Clin Breast Cancer 2021; 21: 80-91.e7 DOI: 10.1016/j.clbc.2020.09.014.
• 52 Chan A, Delaloge S, Holmes FA. et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2016; 17: 367-377 DOI: 10.1016/S1470-2045(15)00551-3.
• 53 Clinicaltrials.gov. A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05). 2022 Online (Stand: 28.12.2022): https://clinicaltrials.gov/ct2/show/NCT04622319
• 54 Ruiterkamp J, Voogd AC, Bosscha K. et al. Impact of breast surgery on survival in patients with distant metastases at initial presentation: a systematic review of the literature. Breast Cancer Res Treat 2010; 120: 9-16 DOI: 10.1007/s10549-009-0670-0.
• 55 Gnerlich J, Dueker JM, Jeffe DB. et al. Patient and tumor characteristics associated with primary tumor resection in women with Stage IV breast cancer: analysis of 1988-2003 SEER data. Breast J 2008; 14: 538-542 DOI: 10.1111/j.1524-4741.2008.00644.x.
• 56 Le Scodan R, Stevens D, Brain E. et al. Breast cancer with synchronous metastases: survival impact of exclusive locoregional radiotherapy. J Clin Oncol 2009; 27: 1375-1381 DOI: 10.1200/jco.2008.19.5396.
• 57 Ali D, Le Scodan R. Treatment of the primary tumor in breast cancer patients with synchronous metastases. Ann Oncol 2011; 22: 9-16 DOI: 10.1093/annonc/mdq301.
• 58 Di Lascio S, Pagani O. Oligometastatic Breast Cancer: A Shift from Palliative to Potentially Curative Treatment?. Breast Care 2014; 9: 7-14 DOI: 10.1159/000358750.
• 59 Cullinane C, Fleming C, OʼLeary DP. et al. Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis. JAMA Network Open 2020; 3: e2026921-e2026921 DOI: 10.1001/jamanetworkopen.2020.26921.
• 60 Sant M, Bernat-Peguera A, Felip E. et al. Role of ctDNA in Breast Cancer. Cancers 2022; 14: 310
• 61 Croessmann S, Park BH. Circulating tumor DNA in early-stage breast cancer: new directions and potential clinical applications. Clin Adv Hematol Oncol 2021; 19: 155-161
• 62 Trapp E, Janni W, Schindlbeck C. et al. Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis. J Natl Cancer Inst 2019; 111: 380-387 DOI: 10.1093/jnci/djy152.
• 63 Huebner H, Haberle L, Muller V. et al. MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients. Cancers (Basel) 2022; DOI: 10.3390/cancers14071721.
• 64 clinicaltrials.gov. Standard Surveillance vs. Intensive Surveillance in Early Breast Cancer (SURVIVE). 2023 Online (Stand: 15.04.2023): https://clinicaltrials.gov/ct2/show/NCT05658172
• 65 Stickeler E, Aktas B, Behrens A. et al. Update Breast Cancer 2021 Part 1 – Prevention and Early Stages. Geburtshilfe Frauenheilkd 2021; 81: 526-538 DOI: 10.1055/a-1464-0953.
• 66 Stiftung SONK St.Gallen Oncology Conferences. Faculty Members – 18^th St. Gallen International Breast Cancer Conference 2023. 2023 Online (Stand: 10.03.2023): https://www.oncoconferences.ch/events/sgbcc-2023/